NovaDel Pharma Inc. (AMEX:NVD) announced that they have received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. Patent Application No. 10/671,715 entitled “Buccal, Polar and Non-Polar Spray containing Zolpidem” that covers a method of treating insomnia by administering zolpidem to human beings utilizing NovaMist Oral Spray spray technology. NovaDel’s oral spray technology is focused for unmet medical needs for a broad array of existing and future pharmaceutical products. The Company’s most advanced oral spray candidates target angina, nausea, insomnia, migraine headaches and disorders of the central nervous system.

NovaDel Pharma is a leading specialty pharmaceutical company that is into the development of oral spray formulations for a broad range of marketed drugs. The Company offers conventional oral dosage forms that has the potential for faster absorption of drugs into the bloodstream that leads to quick therapeutic effects and reduces first pass

Ligand Pharmaceuticals Inc (NASDAQ:LGND) has announced that they have extended their research collaboration with Pfizer for JAK3 by one year. Both the companies had entered the research and license agreement in December 2006 with Wyeth provided for the initial three years research term. Under the extended collaboration agreement, Ligand Pharmaceuticals will receive US$3.1 million in research payments to continue the drug discovery and optimization of their lead candidate. Under the original agreement, Ligand Pharmaceutical was entitled to receive up to US$175 million as milestone payments for the successful development and commercialization of multiple products.

Ligand Pharmaceuticals is one of the growing companies that is into the discovery and development of new drugs that addresses critical unmet medical needs of patients with muscle wasting, hormone related diseases, osteoporosis, anemia, asthma and rheumatoid arthritis. Ligand’s drug discovery and development programs are based on advanced cell-based assays, gene expression tools and one of

China Medicine Corp. is a developer and leading distributor of prescription and over-the-counter drugs, traditional Chinese medicine products, nutritional and dietary supplements, and medical devices and formulations in China.

The company announced today that through its wholly-owned subsidiary in China, Konzern Pharmaceuticals, it has signed an equity transfer agreement to acquire 100% of equity interests in Sinoform Limited, a British Virgin Islands corporation which is the sole shareholder of Guangzhou LifeTech Pharmaceuticals. LifeTech Pharmaceuticals is a developer, manufacturer and marketer of pharmaceutical products and traditional Chinese medicines in China.

The acquisition is expected to close before the end of the year and China Medicine will acquire Guangzhou LifeTech for 57 million renminbi or about $8.3 million cash and the assumption of about $13.2 million in debt. Upon closing of the acquisition, the company will receive all of LifeTech’s assets, including a portfolio of 39 Western and traditional Chinese medicine products. LifeTech’s top-selling

Depomed, Inc (NASDAQ:DEPO) today reported financial results for the third quarter that ended on September 30, 2009. The revenue for the three months ended September 30, 2009 was US$23 million compared to US$14.1 million for the three months ended September 30, 2008. The revenue in the last three months ended this September also includes license payments from Merck &Co. Inc. as Depomed has entered a license agreement with Merck for fixed dose combinations of sitagliptin and extended release metformin which they finalized in July 2009.

Executives of Depomed announced that they have achieved significant milestones in the third and early fourth quarter and have also completed a transaction with Merck that has provided them a reason to rejoice and have a stronger and profitable balance sheet this quarter. Depomed is a specialty pharmaceutical company which has many product candidates in the pipeline with few of products already in Phase 3

CytRx Corporation (NASDAQ:CYTR) has announced that a paper published in Gerontology journal concluded that molecular chaperone amplification may represent a significant strategy in the designing of anti-aging pharmaceuticals in the near future. CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company’s drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a study for the treatment of acute promyelocytic leukemia (APL). CytRx is also developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease.

CytRx believes that the inhibition of molecular chaperones that normally help protect cancer cells from toxic misfolded proteins may result in the selective destruction of cancer cells. CytRx

CytRx Corporation (NASDAQ:CYTR) has announced that a paper published in Gerontology journal concluded that molecular chaperone amplification may represent a significant strategy in the designing of anti-aging pharmaceuticals in the near future. CytRx Corporation is a biopharmaceutical research and development company engaged in the development of high-value human therapeutics. The Company’s drug development pipeline includes programs in clinical development for cancer indications, including tamibarotene in a study for the treatment of acute promyelocytic leukemia (APL). CytRx is also developing two drug candidates based on its industry-leading molecular chaperone technology, which aims to repair or degrade misfolded proteins associated with disease.

CytRx believes that the inhibition of molecular chaperones that normally help protect cancer cells from toxic misfolded proteins may result in the selective destruction of cancer cells. CytRx Corporation currently has two clinical-stage molecular chaperone drug candidates and has discovered a series of additional compounds that may provide a pipeline

Sanofi-Aventis SA (ADR) (NYSE:SNY), France’s biggest pharmaceutical group has accused Hospira Inc and Canada’s Apotex Inc of infringing patents for the cancer drug Taxotere. Sanofi-Aventis has said that both the companies have tried to copy their products. Earlier Sanofi-Aventis have filed separate complaints against Hospira Inc and Apotex Inc that they have violated the patent laws and have attempted to duplicate their top ranging product that is developed and marketed for the treatment of cancer patients. Though the market reacted sharply after the news broke into the market, but there was not much of fluctuation in the shares of Sanofi-Aventis at the end of the day.

Sanofi-Aventis is one of the leading pharmaceutical companies in France and globally as well. The company is into the research, development, manufacturing

Dr Stock Pick HOT News & Alerts!

_________________________________________

FREE Daily Stock Alerts From DrStockPick.com

_________________________________________

Friday October 23, 2009

DrStockPick.com Stock Report!

PSFT, VZ, PWRM, CSRH, HD, CVAT, MRK, AQNM, SGP

**************************************************************

VZ, Verizon Communications Inc.

VZ provides communication services in the United States and internationally. It operates in two segments, Wireline and Domestic Wireless.

Verizon Wireless, the nation’s largest wireless service provider, today announced a new advertising effort, “Don’t Text and Drive,” encouraging people who get into a vehicle’s driver seat to keep their hands on the wheel. Dan Mead, executive vice president and chief operating officer at Verizon Wireless, said the “Don’t Text and Drive” campaign begins next week with a mix of ads, including television, radio,

Encorium Group Inc. is a full-service multinational contract research organization (CRO). They provide design, development, and management capabilities for clinical trials and patient registries. They do this for many of the world’s leading pharmaceutical companies. Trading on the NASDAQ Capital Market, Encorium Group Inc. has offices in 10 countries, managing clinical trials with their own employees. The Company’s corporate headquarters are in Wayne, Pennsylvania.

Encorium Group, Inc. provides their services to the pharmaceutical, biotechnology, and medical device industries. Their corporate mission is to provide their clients with high quality, full-service support for their biopharmaceutical and medical device development programs. They offer therapeutic expertise, experienced team management, and advanced technologies.

Encorium has drug and biologics development as well as clinical trial experience across a broad spectrum of therapeutic areas. These include infectious diseases, cardiovascular, vaccines, oncology, and diabetes endocrinology/metabolism. These also include gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women’s health

Mountain West Business Solutions, Inc. recently announced that the company has acquired Sunshine Biopharma, Inc. Based in Colorado, Sunshine Biopharma is a leading pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer. Mountain West Business Solutions intends to change its name to Sunshine Biopharma, Inc. to reflect the company’s new direction. In addition, Mountain West Business Solutions’ trading symbol will also be changed upon the name change taking effect.

According to the terms of the deal, the acquisition was in exchange for the issuance of 21,962,000 shares of common stock and 850,000 shares of Series “A” convertible preferred stock. Each preferred share can be converted into 20 shares of common stock.

Mountain West Business Solutions also announced that Dr. Steve N. Slilaty has been named chairman, president and chief executive officer; Michele di Turi as chief operating officer and director;